Tealwood Asset Management’s Myriad Genetics MYGN Stock Holding History

Tealwood Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-151,770	Closed	-$3.18M	–	86
2013 Q4	$3.18M	Sell	151,770 -3,205	-2%	-$81.1K	1.28%	36
2013 Q3	$3.64M	Buy	154,975 +64,190	+71%	+$1.82M	1.61%	24
2013 Q2	$2.44M	Buy	+90,785	New	+$2.63M	1.22%	34

Other funds holding MYGN

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Tealwood Asset Management's MYGN Position: Q1 2014 in Review

Tealwood Asset Management sold out of Myriad Genetics (MYGN) in Q1 2014, closing a stake of 151,770 shares — an estimated $3.18M sold.

Tealwood Asset Management first reported a position in MYGN in Q2 2013 and held it in 3 quarters. The position peaked at $3.64M in Q3 2013. 280 funds tracked by Wall St. Rank hold MYGN as of Q1 2014.

Tealwood Asset Management reported no remaining Myriad Genetics position as of Q1 2014 after selling out during the quarter.
Tealwood Asset Management sold 151,770 Myriad Genetics shares in Q1 2014, an estimated $3.18M.
Tealwood Asset Management first reported a position in Myriad Genetics in Q2 2013 and held it in 3 quarters.
Tealwood Asset Management's Myriad Genetics position peaked at $3.64M in Q3 2013.
280 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2014.

Based on Tealwood Asset Management's 13F filing for Q1 2014, filed 6 May 2014.